SHIFT AI Newsroom · UK
Rybelsus (semaglutide tablets) formulation change poses medication error risk
The MHRA has issued a drug safety update regarding the transition to a new formulation of Rybelsus (semaglutide tablets), highlighting the risk of medication errors.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update regarding the transition to a new formulation of Rybelsus (semaglutide tablets). The update highlights the risk of medication errors if healthcare professionals are not aware of the change.
What this means in the UK
This change affects patients in the UK who are taking Rybelsus (semaglutide tablets) for their condition, and healthcare professionals must be aware of the new formulation to prevent medication errors.
Known facts
- The MHRA has issued a drug safety update on the transition to a new formulation of Rybelsus (semaglutide tablets).